Abstract
Hunter syndrome or mucopolysaccharidosis type II (MPS II) is an X-linked recessive disease caused by the deficiency of iduronate 2-sulfatase (IDS), leading to storage of undegraded heparan and dermatan sulfate. Patients with the severe form present neurological abnormalities, but the mechanisms of such alterations are unknown. Here, we hypothesized that the undegraded substances found in this disease could be recognized as damage-associated molecular patterns (DAMPS), leading to activation of the inflammasome. Brains from 2 and 5 months normal and MPS II mice were studied. We observed an increase in cathepsin B activity in the brain tissue and leakage of this enzyme from the lysosome to the cytoplasm in a MPS II neuronal cell line, which is a known activator of the inflammasome. Furthermore, Caspase-1 activity and IL-1-beta levels were elevated at 5 months, confirming that this pathway is indeed altered. Our results suggest that undegraded GAG activate the inflammasome pathway in MPS II and future studies could focus on blocking such pathway to better understand the role of this process to the pathogenesis of MPS II.
This is a preview of subscription content, log in via an institution to check access.
References
Arranz AM, De Strooper B (2019) The role of astroglia in Alzheimer's disease: pathophysiology and clinical implications. Lancet Neurol 18(4):406–414. https://doi.org/10.1016/S1474-4422(18)30490-3
Azambuja AS, Correa L, Gabiatti BP, Martins GR, de Oliveira FÁ, Ribeiro MFM, Baldo G (2018) Versive and non-aversive memory impairment in the mucopolysaccharidosis II mouse model. Metab Brain Dis 33(1):343–345. https://doi.org/10.1007/s11011-017-0110-5
Baldo G, Mayer FQ, Martinelli B, Dilda A, Meyer F, Ponder KP, Giugliani R, Matte U (2012) Evidence of a progressive motor dysfunction in Mucopolysaccharidosis type I mice. Behav Brain Res 233(1):169–175. https://doi.org/10.1016/j.bbr.2012.04.051
Brusius-Facchin AC, Schwartz IV, Zimmer C, Ribeiro MG, Acosta AX, Horovitz D, Monlleó IL, Fontes MI, Fett-Conte A, Sobrinho RP, Duarte AR, Boy R, Mabe P, Ascurra M, de Michelena M, Tylee KL, Besley GT, Garreton MC, Giugliani R, Leistner-Segal S (2014) Mucopolysaccharidosis type II: identification of 30 novel mutations among Latin American patients. Mol Genet Metab 111(2):133–138
Burkovetskaya M, Bosch ME, Karpuk N, Fallet R, Kielian T (2019) Caspase 1 activity influences juvenile Batten disease (CLN3) pathogenesis. J Neurochem 148(5):652–668
Campden RI, Zhang Y (2019) The role of lysosomal cysteine cathepsins in NLRP3 inflammasome activation. Arch Biochem Biophys. https://doi.org/10.1016/j.abb.2019.02.015
DiRosario J, Divers E, Wang C, Etter J, Charrier A, Jukkola P, Auer H, Best V, Newsom DL, McCarty DM, Fu H (2009) Innate and adaptive immune activation in the brain of MPS IIIB mouse model. J Neurosci Res 87(4):978–990
Dunn KW, Kamocka MM, McDonald JH (2011) A practical guide to evaluating colocalization in biological microscopy. Am J Physiol Cell Physiol 300(4):C723–C742
Giugliani R, Vairo F, Kubaski F, Poswar F, Riegel M, Baldo G, Saute JÁ (2018) Neurological manifestations of lysosomal disorders and emerging therapies targeting the CNS. Lancet Child Adolesc Health 2(1):56–68. https://doi.org/10.1016/S2352-4642(17)30087-1
Gleitz HF, O'Leary C, Holley RJ, Bigger BW (2017) Identification of age-dependent motor and neuropsychological behavioural abnormalities in a mouse model of Mucopolysaccharidosis Type II. PLoS One 12(2):e0172435. https://doi.org/10.1371/journal.pone.0172435
Gonzalez EA, Martins GR, Tavares AMV, Viegas M, Poletto E, Giugliani R, Matte U, Baldo G (2018) Cathepsin B inhibition attenuates cardiovascular pathology in mucopolysaccharidosis I mice. Life Sci 196:102–109. https://doi.org/10.1016/j.lfs.2018.01.020
Harris J, Hartman M, Roche C, Zeng SG, O'Shea A, Sharp FA, Lambe EM, Creagh EM, Golenbock DT, Tschopp J, Kornfeld H, Fitzgerald KA, Lavelle EC (2011) Autophagy controls IL-1beta secretion by targeting pro-IL-1beta for degradation. J Biol Chem 286(11):9587–9597
Jacques CE, Donida B, Mescka CP, Rodrigues DG, Marchetti DP, Bitencourt FH, Burin MG, de Souza CF, Giugliani R, Vargas CR (2016) Oxidative and nitrative stress and pro-inflammatory cytokines in Mucopolysaccharidosis type II patients: effect of long-term enzyme replacement therapy and relation with glycosaminoglycan accumulation. Biochim Biophys Acta 1862(9):1608–1616
Kawashita E, Tsuji D, Kawashima N, Nakayama K, Matsuno H, Itoh K (2009) Abnormal production of macrophage inflammatory protein-1alpha by microglial cell lines derived from neonatal brains of Sandhoff disease model mice. J Neurochem 109(5):1215–1224. https://doi.org/10.1111/j.1471-4159.2009.06041.x
Latz E (2010) The inflammasomes: mechanisms of activation and function. Curr Opin Immunol 22(1):28–33
Parker H, Bigger BW (2019) The role of innate immunity in mucopolysaccharide diseases. J Neurochem 148(5):639–651
Parker H, Ellison SM, Holley RJ, O'Leary C, Liao A, Asadi J, Glover E, Ghosh A, Jones S, Wilkinson FL, Brough D, Pinteaux E, Boutin H, Bigger BW (2020) Haematopoietic stem cell gene therapy with IL-1Ra rescues cognitive loss in mucopolysaccharidosis IIIA. EMBO Mol Med 12(3):e11185
Schroder K, Tschopp J (2010 Mar 19) The inflammasomes. Cell. 140(6):821–832
Settembre C, Fraldi A, Jahreiss L, Spampanato C, Venturi C, Medina D, de Pablo R, Tacchetti C, Rubinsztein DC, Ballabio A (2008) A block of autophagy in lysosomal storage disorders. Hum Mol Genet 17(1):119–129
Simonaro CM (2016) Lysosomes, Lysosomal storage diseases, and inflammation. Journal of Inborn Errors of Metabolism 4:1–8. https://doi.org/10.1177/2326409816650465
Simonaro CM, Ge Y, Eliyahu E, He X, Jepsen KJ, Schuchman EH (2010) Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses. Proc Natl Acad Sci U S A 107(1):222–227. https://doi.org/10.1073/pnas.0912937107
Tschopp J, Schroder K (2010) NLRP3 Inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat Rev Immunol 10(3):210–5. https://doi.org/10.1038/nri2725
Zalfa C, Verpelli C, D'Avanzo F, Tomanin R, Vicidomini C, Cajola L, Manara R, Sala C, Scarpa M, Vescovi AL, De Filippis L (2016) Glial degeneration with oxidative damage drives neuronal demise in MPSII disease. Cell Death Dis 7(8):e2331. https://doi.org/10.1038/cddis.2016.231
Acknowledgments
The authors would like to thank Casa Hunter, Conselho Nacional de Desenvolvimento Cientifico, CAPES, FAPERGS and Fundo de Incentivo a Pesquisa do HCPA for financial support. The authors declare no conflict of interest regarding the content of this manuscript. The authors certify that they have no involvement in any organization or entity with any financial interest or non-financial interest in the subject matter discussed in this manuscript.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Azambuja, A.S., Pimentel-Vera, L.N., Gonzalez, E.A. et al. Evidence for inflammasome activation in the brain of mucopolysaccharidosis type II mice. Metab Brain Dis 35, 1231–1236 (2020). https://doi.org/10.1007/s11011-020-00592-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11011-020-00592-5